Pluristem (PSTI) Fair Value & Analysis

Healthcare · Il · Market cap 117M ILA · ISIN US72940R3003

Below-average quality, and trading another 369% above our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (1.20 ILA). The favourable scenario is already priced in.
• Weak quality (11/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (0.6300 ILA to 1.20 ILA) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.

How to read this chart

60‑month range 4.50 ILA – 130.32 ILA · fair‑value band 0.6300 ILA – 1.20 ILA · the 4.50 ILA price screens above the 0.9600 ILA fair value. Dashed = 300-day average. As of Aug 28, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Pluristem (PSTI) currently trades at 4.50 ILA, while our model-based Fair Value estimate is 0.9600 ILA, implying the stock looks roughly 78.7% overvalued today. The Quality Score stands at 11/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at 234K ILA. Revenue declined 54.0% year over year. It earns a return on equity of -86.6%. Fundamentals as of Aug 28, 2026

Our scenario range runs from 0.6300 ILA (bear case) to 1.20 ILA (bull case); at 4.50 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -37% fair-value upside, at -79%, PSTI screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions.

Full company description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2017 – FY2021 · reported fiscal years

Pluristem reported revenue of 0 ILA in FY2021 versus 0 ILA in FY2017. Reported net income was −49.9M ILA in FY2021.

PSTI screens 79% overvalued. Compare with MEDIPOST Co →

Peer Group

Health Care · 2460 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)

Valuation Multiples vs Health Care median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.